You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy. This site is protected by ...

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Johnson & Johnson JNJ is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing ...